ライフサイエンスコーパス: iron dextran

1 s, was increased three-fold by high doses of iron dextran.

2 one to 15 weekly subcutaneous injections of iron dextran.

3 ability shift were revealed below 500 mug/mL iron dextran.

4 t mice that included daily administration of iron dextran.

5 iron carbonyl in the diet, or injected with iron dextran.

6 ongolian gerbil given repeated injections of iron dextran.

7 e absence of administered iron, but not when iron dextran (300-500 mg Fe/kg) was administered.

8 ly subcutaneous injections of either 1 mL of iron dextran (5 mg/mL) or 0.9% NaCl for a total of five

9 red within a 12-week period was highest with iron dextran (82 per 100,000 persons, 95% CI, 70.5- 93.1

10 irst exposure was 68 per 100,000 persons for iron dextran (95% CI, 57.8-78.7 per 100,000) and 24 per

11 We examined the effects of chronic iron dextran administration (15 mg over 6 weeks) on thro

12 Neither an Hfe-null mutation nor iron-dextran administration alone or in combination with

13 omozygosity for an Hfe-null mutation but not iron-dextran administration was porphyrinogenic in anima

14 n but not to the extent seen with parenteral iron-dextran administration.

15 High-dose iron supplementation with iron dextran after the onset of sepsis significantly inc

16 ron, the risk of anaphylaxis was highest for iron dextran and lowest for iron sucrose.

17 /-) zebrafish were rescued by injection with iron dextran and studied in comparison with injected and

18 When URO-D(+/-) mice were injected with iron-dextran and given drinking water containing delta-a

19 l mutation and polychlorinated biphenyls and iron-dextran and polychlorinated biphenyls.

20 with 1.2 g elemental iron/kg body weight as iron dextran) and pair-fed control groups.

21 erated an iron-overloaded mouse by injecting iron dextran at 2 doses into C57/BL6 mice for 2 months.

22 Iron, administered as an iron dextran complex or as a 1:1 chelate with nitrilotri

23 KIM5-infected mice treated daily with 4 mg iron dextran died in 3 days with severe pneumonia.

24 against KIM5 infections in mice administered iron dextran doses leading to light or severe pneumonia,

25 MDA was considerably increased even at low iron dextran doses, but without any increase in URO accu

26 Mice were first treated with iron dextran for 4 weeks to induce iron-overload cardiom

27 Administrations of IV iron dextran, gluconate, sucrose, or ferumoxytol as repo

28 f HIF-2alpha or parenteral administration of iron-dextran in HIF-2alpha knockout mothers ameliorated

29 ethanol for 6 to 7 months, administration of iron dextran increased hepatic URO accumulation and decr

30 ) deformability in vitro was assessed during iron dextran (INFeD) loading and/or ethanol co-administr

31 ls < 600 ng/mL were treated with intravenous iron dextran (INFeD; Schein Pharmaceutical Inc., Florham

32 uptake than wild-type littermates following iron dextran injection.

33 pplemented either directly in the diet or by iron dextran injection.

34 Injection of iron dextran into WT or mutant zebrafish embryos, howeve

35 nes the effects of a maintenance intravenous iron dextran (ivID) protocol that increased TSAT in ESRD

36 Twelve gerbils underwent iron dextran loading (200 mg . kg(-1) . wk(-1)) from 2 t

37 ed significant cell stiffening at 500 mug/mL iron dextran loading concentration (p < 0.05, Tukey test

38 dequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit

39 increased systemic iron availability (e.g., iron dextran or phenylhydrazine) on the induction, kinet

40 erloaded mice, including models of acquired (iron-dextran or stored red blood cells) and primary (Hfe

41 nted when prescribing >10 vials (1000 mg) of iron dextran over a period of 6 mo.

42 iron; (2). oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextra

43 high-iron diet or by parenteral injection of iron dextran; rescue can also be achieved by providing a

44 en they were injected intraperitoneally with iron dextran, though not with iron sulfate.

45 iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI).

46 ains containing pGTR902 were inoculated into iron dextran-treated and untreated mice.

47 lesions in subcutaneously (s.c.) inoculated iron dextran-treated mice in terms of numbers of recover

48 results demonstrate that s.c. inoculation of iron dextran-treated mice is a useful model for studying

49 V. vulnificus inoculated into iron dextran-treated mice replicated extremely rapidly o

50 Studies with iron dextran-treated mice showed that vaccination with t

51 Infection of non-iron dextran-treated mice with clinical strains demonstr

52 In non-iron dextran-treated mice, strains required 10(5)-fold-h

53 ls of virulence in subcutaneously inoculated iron dextran-treated mice.

54 es adherence to HEp-2 cells and virulence in iron dextran-treated mice.

55 n period were not significantly different in iron dextran-treated mice; however, the rate of death of

56 r severe pneumonia, supporting the use of an iron dextran-treated model of pneumonic plague.

57 ly attenuated in a subcutaneously inoculated iron dextran-treated mouse model of V. vulnificus diseas

58 for virulence in a subcutaneously inoculated iron dextran-treated mouse model.

59 d for virulence in subcutaneously inoculated iron-dextran-treated mice.

60 erapeutic agents against V. vulnificus in an iron-dextran-treated mouse model of V. vulnificus infect

61 o cause an identical disease process as with iron dextran treatment.

62 ins demonstrated that the greatest effect of iron dextran-treatment was increased growth rate, while

63 sucrose, the adjusted OR of anaphylaxis for iron dextran was 3.6 (95% CI, 2.4-5.4); for iron glucona

64 Pneumonia was less severe if 4 mg iron dextran was administered only once before infection

65 Iron dextran was required in the bacterial inoculum to e